← Eichor
Condition: T Cell Leukemia Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: T Cell Leukemia Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481241MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NA · 1 location(s) · King Hussein Cancer Center · NCT07371403MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Phase 2 · 1 location(s) · Daihong Liu · NCT07321301A Study of CTD402 in T-ALL/LBL Patients
Phase 1/Phase 2 · 8 location(s) · Imviva Bio · NCT07070219In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Phase 2 · 1 location(s) · Ascentage Pharma Group Inc. · NCT04496349NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05262673CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06503094CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Phase 1 · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06752785CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
Phase 1/Phase 2 · 1 location(s) · Bambino Gesù Hospital and Research Institute · NCT06064903Newly-diagnosed Pediatric T-cell ALL Protocol
Phase 2/Phase 3 · 27 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06855810CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Phase 1/Phase 2 · 1 location(s) · Affiliated Hospital to Academy of Military Medical Sciences · NCT06834529AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Le
Phase 2 · 15 location(s) · Goethe University · NCT06648889Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
Phase N/A · 1 location(s) · N.N. Alexandrov National Cancer Centre · NCT07524816Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · 2 location(s) · University of Kansas Medical Center · NCT03533816Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
EARLY_Phase 1 · 1 location(s) · Tan Jie · NCT06659653A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Phase 1 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT05010005The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Phase 1/Phase 2 · 9 location(s) · Juventas Cell Therapy Ltd. · NCT05667506A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
EARLY_Phase 1 · 1 location(s) · Affiliated Hospital of Nantong University · NCT06756321CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 7 location(s) · British Columbia Cancer Agency · NCT06208735Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Phase 1/Phase 2 · 19 location(s) · Cellectis S.A. · NCT04150497Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Phase 1 · 16 location(s) · New York Medical College · NCT04972942
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.